NOACs is the abbreviation of new oral anticoagulants, NOACs mainly include two types of direct thrombin inhibitors and inhibitors of factor Xa, the former includes dabigatran and the latter includes apixaban, edoxaban and rivaroxaban, etc. Traditional anticoagulants usually act on multiple coagulation factors, while NOACs only inhibit one coagulation factor. Conventional anticoagulants usually act on multiple coagulation factors, whereas NOACs are anticoagulants that inhibit only one coagulation factor.The pharmacokinetic properties of NOACs are more stable, less affected by drugs, food and other factors, and are characterized by a fast onset of action, short half-life, and ease of use that does not require frequent monitoring. NOACs can be applied to most patients, and there is no significant difference in effect for patients of different ages, genders and races. It should be noted that dabigatran needs to be swallowed whole and cannot be divided or chewed.NOACs are not currently used for thromboembolism prophylaxis after mechanical valve replacement. This kind of drug medicine adverse reactions for bleeding, need to be under the guidance of a professional doctor, not unauthorized use of drugs, it is recommended that the patient to consult a professional hospital for diagnosis and treatment.